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Abstract
Background: Clusterin is a secreted glycoprotein that is upregulated in a variety of cell lines in response to stress,
and enhances cell survival. A second nuclear isoform of clusterin that is associated with cell death has also been
identified. The aim of this study was to determine the role(s) of the secretory isoform in breast tumor progression
and metastasis.
Methods: To investigate the role of secretory clusterin in the biology of breast cancer tumor growth and
resistance to therapy we have engineered an MCF-7 cell line (MCF-7CLU) that over-expresses clusterin. We have
measured the in vitro effects of clusterin over-expression on cell cycle, cell death, and sensitivity to TNFalpha and
tamoxifen. Using an orthotopic model of breast cancer, we have also determined the effects of over-expression of
clusterin on tumor growth and metastatic progression.
Results: In vitro, over-expression of secretory clusterin alters the cell cycle kinetics and decreases the rate of cell
death, resulting in the enhancement of cell growth. Over-expression of secretory clusterin also blocks the
TNFalpha-mediated induction of p21 and abrogates the cleavage of Bax to t-Bax, rendering the MCF-7CLU cells
significantly more resistant to the cytokine than the parental cells. Orthotopic primary tumors derived from MCF-
7CLU cells grow significantly more rapidly than tumors derived from parental MCF-7 cells and, unlike the parental
cells, metastasize frequently to the lungs.
Conclusions: These data suggest that secretory clusterin, which is frequently up-regulated in breast cancers by
common therapies, including anti-estrogens, may play a significant role in tumor growth, metastatic progression
and subsequent drug resistance in surviving cells.
Background
The development of a metastatic, hormone-independent
and drug resistant phenotype is responsible for a high
percentage of treatment failures among breast cancer
patients. Therefore, understanding the molecular
mechanisms of metastasis is crucial for the design and
effective use of novel therapeutic strategies to combat
tumor progression [1-3]. Whether the phenotypes of
drug resistance, hormone independence and invasion
are linked genotypically, or whether they involve inde-
pendent genetic or epigenetics processes, remains to be
determined. Clusterin is a secreted heterodimeric 70-80
kDa glycoprotein composed of alpha and beta chains
linked by five inter-chain disulfide bonds [4,5]. The
glycoprotein is induced during apoptosis in hormone
dependent tissues including the prostate and mammary
gland [6,7], as well as many other tissues in response to
stress [8-11], although it is not clear whether the protein
plays a pivotal mechanistic role in either cell death or
cell survival since it is also expressed constitutively in
many tissues [9,11].
In MCF-7 breast cancer cells, the biogenesis of clus-
terin is significantly altered during tamoxifen-induced
apoptosis, and a new isoform of the protein appears in
the nucleus [12]. While the details of the changes in the
intracellular trafficking that produce this new isoform
have not been fully elucidated, it is clear that the
nuclear isoform is not cleaved to form the alpha and
beta chains and is not glycosylated, even though the
protein appears to retain its disulfide linkages [12].
Increases in a nuclear form of clusterin in response to
radiation [13], heat shock [14] and other stress inducers
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clear consensus on the biogenesis or structure of the
nuclear protein or its function. The nuclear isoform pro-
duced by radiation is known to bind to Ku70/80, inhi-
biting non-homologous end joining (NHEJ) DNA repair
during apoptosis [18]. While the synthesis of clusterin
and the appearance of the nuclear isoform is clearly
upregulated during apoptosis, the role of the secretory
protein in either cell death or cell survival has not been
clearly delineated.
The physiological function of secreted the glycosylated
isoform is not fully understood, but it most likely serves
as a extracellular chaperone [19], although the struc-
ture-function relationship remains to be firmly estab-
lished [4,20]. The protein is also known to bind to
cholesterol and other hydrophobic ligands [21], giving
rise to the suggestion that it is responsible for the retro-
grade transport of cholesterol and proteins in redundant
membranes produced by apoptotic cells to the liver.
Pathological or engineered over-expression of clusterin
in various cell types confers resistance to the induction
of apoptosis by several cytokines including TGFbeta,
and TNFalpha [22-24] and promotes tumor progression
in the prostate [25,26]. Thus, while the protein is clearly
expressed in cells that are destined to undergo apopto-
sis, the observation that high levels of clusterin expres-
sion is also seen in surviving cells suggests that it may
play a role in cell survival. Elevated clusterin expression
generally correlates with tumor grade in prostate cancer
[27-29], although at least one report has shown that the
level of clusterin mRNA in prostate cancer is lower than
in paired benign tissue from the organ [30]. Clusterin is
currently being targeted using anti-sense RNA
approaches in clinical trials for prostate cancer disease
[31]. In breast cancer, two small retrospective studies
has shown an association with elevated clusterin expres-
sion and large tumor size, estrogen and progesterone
receptor status and with the progression from the pri-
mary carcinoma to metastatic carcinoma in lymph
nodes in breast cancer [32,33]. The studies described
here are designed to investigate whether secretory clus-
terin expression plays a causative role in the progression
of human breast carcinoma.
Methods
Cell culture
MCF-7 (American Type Culture Collection, Rockville,
MD), MCF-7CLU and SUM-159PT (University of
Michigan Human Breast Cell/Tissue Bank, Ann Arbor,
MI) were cultured in alpha-MEM medium (Life Tech-
nologies Inc, Gaithersburg, MD) containing 25 mM
HEPES and 5% fetal bovine serum (ATLAS Biologicals,
Fort Collins, CO). Cells were routinely passaged every
4-5 days. For cell growth and morphological assays,
MCF-7 and MCF-7CLU cells were plated at either
10,000 or 20,000 cells/well in 24-well plates and were
treated with 1, 5 or 10 micromolar tamoxifen (Sigma,
St. Louis, MO), or 1, 5 or 10 ng/ml TNFalpha(Sigma) or
ethanol vehicle for the indicated times, starting two days
after plating.
Over-expression of clusterin
MCF-7 cells were engineered to over-express the glyco-
sylated clusterin isoform using Gateway Technology
(Invitrogen Corporation, Carlsbad, California) according
to the manufacturer’s protocol. Briefly, Gateway’s attB1
and attB2 recombination sites were added to the 5’ and
3’ ends respectively of human clusterin cDNA [34] by
PCR amplification using primers containing the attB
sites. Using Gateway Technology, which allows for the
transfer of DNA among different vectors based on
lambda-phage recombination, the clusterin cDNA was
inserted into the pDONOR 201 plasmid to generate the
entry clone. This vector was subsequently transferred
into the pcDNA-DEST47 destination vector to create
the expression clone pEXP-CLU which allows for con-
stitutive gene expression under the control of a CMV
promoter. A second construct was also engineered in
which the stop codon was altered by a single base pair
mutation of TGA to GGA yielding a glycine residue
substitution. This alteration was generated to allow for
expression of a C-terminal GFP-tagged clusterin (pEXP-
CLUGFP). The construct mutations and correct transfer
into pcDNA-DEST47 were confirmed in all cases by
automated DNA sequencing.
The expression constructs (pEXP-CLU and pEXP-
CLUGFP) were independently transfected into MCF-7
cells using Lipofectamine 2000 (GibcoBRL) according to
the manufacturer’s direction and MCF-7CLU cells were
selected for by growth in appropriate media containing
neomycin (BRL, Gaithersberg, MD).
Cell growth was determined by crystal violet assays.
For quantitation of total adherent cell number, cells
were fixed with 1% gluteraldehyde (Fisher Scientific,
Pittsburgh, PA) for 15 min, incubated with 0.1% crystal
violet (Fisher Scientific) for 30 min, destained with H2O,
and solubilized with 0.2% Triton X-100 (Sigma). Absor-
bance at 590 nm, which is proportional to total adherent
cell number, was determined on a microplate reader.
PCR analysis
DNA was isolated from MCF-7 and MCF-7CLUGFP
cells using a commercially available assay according to
the manufacturer’s protocol (Qiagen, Valencia, CA). Pri-
mers were designed that spanned the CLUGFP gene
sequence and the pcDNA-DEST vector. DNA was
amplified directly using primers specific for the CLU-
pcDNA-DEST vector to generate a product of 380 bp.
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follows:
5’primer: 5’-TCC CAC ACT TCT GAC TCG GAC
GTT C-3’
3’primer: 5’-GCA TCA CCT TCA CCC TCT CCA
CTG A-3’
The amplification conditions were as follows: A dena-
turation step for 5 min at 95°C, followed by 45 sec at
95°C, 45 sec at 64°C and 45 sec at 72°C for 30 cycles,
followed by 15 min at 72°C. 20 microliters of the PCR
reaction was analyzed on a 1.5% agarose gel.
Fluorescence microscopy
MCF-7 and MCF-7CLU cells were plated at 10,000
cells/well onto poly-L-lysine coated Lab-Tek II chamber
slides (Fisher Scientific) and fixed in 4% formaldehyde
after 72 h growth. Cells were analyzed by phase and
fluorescence microscopy and photographed using an
Olympus AX70 microscope equipped with a Spot RT
digital camera.
Flow cytometry
MCF-7 and MCF-7CLU cells were plated at a density of
8×1 0
5 cells/150-mm flask. 48 h following plating, cells
were treated with 1, 2.5 or 5 micromolar tamoxifen or
1, 2.5 or 5 ng/ml TNFalpha or ethanol vehicle for
the indicated times. For analysis of cell cycle kinetics,
MCF-7 and MCF-7CLU cells were harvested by trypsi-
nization, pooled with floating cells, pelleted by centrifu-
gation (500 × g, 5 min, 4°C), fixed and permeabilized
with 90% ethanol at -20°C. Cells were stained with 5
micrograms/ml propidium iodide (Sigma) containing
RNase A (Roche Molecular Biochemicals, Mannheim,
Germany). For analysis of DNA fragmentation, MCF-7
and MCF-7CLU cells were harvested by trypsinization
at the indicated times, collected by centrifugation, fixed
in 2% formaldehyde in PBS, and permeabilized in 70%
ethanol at -20°C. DNA strand breaks in cells under-
going apoptosis were indirectly labeled with bromo-
deoxyuridine by terminal transferase (Roche Molecular
Biochemicals) and detected by FITC-conjugated mono-
clonal antibody to bromodeoxyuridine using the APO-
BrdU kit according to manufacturer’s protocol (Phoenix
Flow Systems, San Diego, CA). Cells were counter-
stained with 5 microgram/ml propidium iodide contain-
ing RNase A for detection of total DNA, and two-color
analysis of DNA strand breaks and cell cycle was
achieved by flow cytometry. All flow cytometric analyses
were performed on an Epics XL Flow Cytometer (Coul-
ter Corp., Miami, FL) equipped with an argon laser.
Data was modeled with the Multiplus AV software
(Phoenix Flow Systems).
Preparation of cell lysates, conditioned media and
subcellular fractions
For cell lysates, monolayers were washed with PBS,
scraped into 2 × Laemlli buffer (containing protease and
phosphatase inhibitors) and sonicated prior to protein
determination using the BCA protein assay (Pierce,
Rockland, IL).
For conditioned media fractions, serum free media
from cells was centrifuged (500 × g, 5 min, 4°C) to pel-
let any floating cells and concentrated using ultra-centri-
fugation filter units (5 KDa cut-off) according to the
manufacturer’s protocol (Fisher Scientific).
For subcellular fractions, adherent and floating cells
were pelleted by centrifugation (500 × g, 5 min, 4°C),
resuspended in wash buffer (25 mM Tris pH 7.5, 250
mM sucrose, 2.5 mM MgCl2, protease and phosphatase
inhibitors), pelleted (500 × g, 5 min, 4°C), resuspended
in 3 volumes of buffer A (20 mM HEPES-KOH, pH 7.5,
10 mM KCL, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 250 mM sucrose, protease and phosphatase inhi-
bitors), lysed with a Dounce homogenizer, and fractio-
nated by differential centrifugation. Briefly, homogenates
were centrifuged twice (500 × g, 5 min, 4°C) and the
supernatants transferred to an ultracentrifuge tube. The
pellets (containing nuclei) were resuspended in Buffer
A, sonicated and stored at -80°C. The combined super-
natants were ultracentrifuged (100,000 × g, 1 h, 4°C) to
generate the cytosolic fraction (supernatant) and the
non-nuclear membrane fraction (NNMF) (pellet). The
pellets were resuspended in 100 ml Buffer A, sonicated
and stored at -80°C. All protein samples were analyzed
for total protein using the Micro BCA protein assay
(Pierce, Rockford, IL).
Western blot analysis
Subcellular fractions, conditioned media, or cell lysates
isolated as described above were solubilized in Laemmli
sample buffer, separated under reducing conditions by
SDS-PAGE and transferred to nitrocellulose. Proteins
derived from the NNMF and cytosolic extracts were
immunoblotted with a rabbit polyclonal antibody direc-
ted against Bax (Clone 13666E; Pharmingen, San Diego,
CA) and normalized for protein loading with mouse
monoclonal antibodies directed against GAPDH (Clone
6G5; Biogenesis, Brentwood, NH) and ATP synthase
( M o l e c u l a rP r o b e s ,I n c . ,E u g e n e ,O R )d i l u t e d1 : 5 0 0 ,o r
1:1000 respectively. Proteins derived from nuclear frac-
tions were immunoblotted with a mouse monoclonal
antibody directed against p21
WAF1 (Clone EA10; Calbio-
chem, San Diego, CA) diluted 1:50. Protein samples
were normalized by comparison to a mouse monoclonal
antibody antibodies directed against lamin A/C (Clone
sc-7293; Santa Cruz, Santa Cruz, CA) diluted 1:100. Pro-
teins derived from cell lysates were immunoblotted with
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6F11; Nova Castra, New Castle upon Tyne, UK) or clus-
terin (Clone 7D1; RDI, Flanders, NJ) diluted 1:50 and
1:1000 respectively and normalized for protein loading
by immunoblotting with GAPDH antibody. All antibo-
dies were diluted in PBS plus 5% skim milk. Proteins
derived from conditioned media were immunoblotted
with anti-clusterin antibody (Clone 7D1; RDI, Flanders,
NJ). Specific antibody binding was detected by the
appropriate horseradish peroxidase-conjugated second-
ary antibodies (BioRad, Hercules, CA) diluted 1:5000 in
PBS plus 5% skimmed milk and detected using
enhanced chemiluminescence. (Pierce, Rockford, IL).
The band intensities were measured and analyzed with
the Kodak 1D imaging software. Changes in protein
levels were normalized relative to the appropriate load-
ing control (lamin A/C for the nuclear fraction; GAPDH
for the cytosolic fraction, and ATP-synthase-alpha for
the mitochondrial fraction) and then plotted relative to
the appropriate control (which was normalized to a
value of 1).
Matrigel invasion assay
Invasion was assessed using 8 micron invasion chambers
coated with growth factor reduced Matrigel™ (Becton
Dickinson, Bedford, MA) according to the manufac-
turer’s protocol with the exception that fibroblast condi-
tioned media (from NIH 3T3 cells) was used as a
chemo-attractant. The number of invasive MCF-7,
MCF-7CLU and SUM-159PT cells was determined 24 h
after 1 × 10
4 cells were seeded into the Matrigel™ cham-
b e r s .A tt h a tt i m et h eM a t r i g e l ™ was removed from the
inserts and the cells on the underside of the membranes
were fixed using 1% gluteraldehyde for 15 min, stained
with 0.1% crystal violet for 30 min and rinsed with
water to remove unbound dye. Membranes were dried,
and numbers of invasive cells on each insert were
counted by viewing under an Olympus AX70
microscope.
Orthotopic xenograft of MCF-7CLU cells
Six week old ovariectomized female NCr-nu mice
(Taconic Farms, Germantown, NY) supplemented with
17-beta-estradiol-sustained release pellets (1.7 mg/90
days) (Innovative Research, Sarasota, FL), were used as
hosts for MCF-7 and MCF-7CLU xenografts. Mice were
inoculated orthotopically with 2 × 10
6 cells/0.1 ml injec-
tion directly into the inguinal mammary fat pad under
anesthesia. Body weight and tumor size was monitored
weekly by caliper measurements of the length, width
and height, and volume was calculated using the for-
mula for a semi-ellipsoid (4/3Br
3/2). When tumor
volume reached approximately 200 mm
3 (4-5 weeks),
mice were randomized to control or tamoxifen
treatment groups. Anesthetized mice were implanted
subcutaneously with placebo or tamoxifen (15 mg/60
day) continuous release pellets. After 6 weeks of treat-
ment, mice were euthanized, blood was collected by car-
diac puncture, tumors and organs were removed,
examined and fixed in 4% formalin (Fisher Scientific) for
histological analysis. All animal studies were carried out
in accordance with an IACUC-approved protocol at the
University of Notre Dame.
Histological analysis of tumors and organs
For routine morphological assessment, tumors and
organs were embedded in paraffin, sectioned at 5
microns, and stained with hematoxylin (Gill’sf o r m u l a -
tion 3, Fisher Scientific) and eosin Y (Sigma, St. Louis,
MO). Mitotic and apoptotic cells were identified by
immunohistochemistry for proliferating cell nuclear
antigen (PCNA) and by TUNEL assay. For PCNA, sec-
tions were incubated with mouse monoclonal anti-
PCNA (Nova Castra Laboratories) at a 1:50 dilution in
1% BSA-PBS. The secondary biotin conjugated antibody
(Vector Laboratories, Burlingame, CA) was applied at a
1:200 dilution in 1% BSA-PBS. The ABC technique fol-
lowed by diaminobenzidine was used to localize peroxi-
dase, and sections were counterstained with Harris’
modified hematoxylin (Fisher). TUNEL was performed
with a commercially available assay according to manu-
facturer’s directions (Boehringer Mannheim, Indianapo-
lis, IN).
For quantitation of proliferation and apoptosis PCNA
and TUNEL positive cells were counted as a percentage
of total cells. At least 4 mice from each group were cho-
sen and 2 tumor sections (approximately 500 cells/sec-
tion) from each mouse were quantitated for PCNA and
TUNEL positivity.
Statistical analyses
Statistical comparisons were performed using Student’s
unpaired t tests (for two groups) or one-way non-para-
metric ANOVA for more than two groups. Data are
expressed as the mean ± SD or mean ± SEM, depending
on the context as indicated in the figure legends, and
differences between means were considered significant
at P < 0.05.
Results
Stable transfection of MCF-7 cells with the pEXP-CLU
using the Gateway expression system resulted in the
integration of approximately 1-2 copies per cell, giving
rise after selection to an MCF-7 cell line constitutively
expressing secretory clusterin. This cell line was desig-
nated MCF-7CLU (Figure 1 panel A). One drawback of
the Gateway system is that it is not possible to produce
a companion empty vector control. We have therefore
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Page 4 of 14Figure 1 Over-expression of clusterin in MCF-7 cells. Panel A: Stable transfection of clusterin into MCF-7 cells using the Gateway pDEST-
clusterin, verified by PCR amplification. Following stable transfection into MCF-7 cells using the pDEST-CLU generated by the Gateway
technology, nuclear DNA was prepared from MCF-7 and MCF-7CLU cells and analyzed for plasmid integration by PCR amplification using
clusterin and vector DNA sequences derived from the clusterin cDNA and the vector. The pEXP-clusterin was used as a positive control. Panel B:
Cell lysates (30 micrograms) and conditioned medium (50 microliters) prepared from MCF-7 and MCF-7CLU before and after 48 h of incubation
in serum free medium were separated on 12.5% SDS-PAGE gels and immunoblotted with mouse monoclonal antibodies against clusterin and
GAPDH. Blots are representative of three independent experiments. Panel C: Comparison of baseline expression of the intracellular clusterin
protein expression in MCF-7 and MCF-7CLU cells were normalized against GAPDH. Panel D: Localization of GFP-tagged clusterin in stably
transfected MCF-7 cells. MCF-7 and MCF-7CLU cells were seeded onto poly-L-lysine coated chamber slides and grown for 48 h prior to fixing
and photography. Scale bar: 25 micrometers. Panel E: Relative expression of pS2 in MCF-7 and MCF-7CLU cells in response to estradiol. MCF-7
and MCF-7CLU cells were grown in the presence of absence of estradiol and/or 10 micromolar tamoxifen for 48 h. RNA was extracted and the
level of relative pS2 mRNA was determined by RT-PCR.
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lel as the control for these experiments. The intracellu-
lar levels of clusterin in the MCF-7 CLU cell line is
increased between 10-15 fold by 48 h compared to the
parental line (Figure 1 panels B and C). This is reflected
by a substantial increase in the levels of extracellular
clusterin (Figure 1 panel B), however since it is not pos-
sible to normalize the levels of extracellular clusterin, it
is only possible to state that the transfected cell line
secretes approximately 10-15 times more clusterin than
the untransfected, unstressed MCF-7 cells. It is also
important to recognize that parental MCF-7 cells also
secrete measurable levels of clusterin over the 48 h col-
lection time. The chimeric GFP tagged clusterin protein
is excluded from the nucleus and is localized within the
endomembrane system, as indicated by the punctate
fluorescence, rather than the diffuse staining typical of
cytoplasmic localization (Figure 1 panel D). MCF-7 cells
over-expressing clusterin retain their sensitivity to both
estrogens and anti-estrogens as assessed by monitoring
the changes in the steady state level of the estrogen tar-
get gene, pS2, by real time PCR (Figure 1 panel E).
While the basal level of pS2 mRNA is elevated in
untreated MCF-7CLU cells relative to the parental cell
line, the estrogen induced expression of pS2 mRNA,
and the responsiveness to tamoxifen is essentially
equivalent in the parental and MCF-7CLU cell lines,
indicating that clusterin over expression has not signifi-
cantly altered the ability of the estrogen receptor to
transactivate known target genes.
MCF-7CLU cells grow more rapidly than untrans-
fected MCF-7 cells (Figure 2 panel A). Flow cytometry
demonstrates that this increase in cell number is not
associated with dramatic changes in cell cycle (Table 1)
but is associated with a significant decrease in apoptosis
in MCF-7CLU compared to the parental MCF-7 cells
(Table 2). In untransfected MCF-7 cells, TNFalpha
induces a decrease in the proportion of cells in S phase
with a concomitant increase in the proportion of cells in
G0/G1 (Table 1) as well as an increase in the percentage
of apoptotic cells (Table 2). Stable transfection of secre-
tory clusterin abrogates the effects of TNFalpha and
tamoxifen on cell cycle kinetics and apoptosis in MCF-
7CLU cells, resulting in the overall increase in cell num-
ber (Figure 2 panel A). Clusterin over-expression confers
significant resistance to TNFalpha, and partial resistance
to tamoxifen (since MCF-7CLU cells appear to show
resistance to 1 micromolar tamoxifen (Figures 2 panels
B and C).
In untransfected MCF-7 cells, TNFalpha induces the
expression of p21 (Figure 3 panel A) and stimulates the
proteolytic activation of Bax, an upstream regulatory
protein that initiates mitochondrial membrane perme-
ability transition and is surrogate marker for cell death.
In contrast in MCF-7 CLU cells, over-expression of
secretory clusterin appears to block the effects of
TNFalpha on both cell cycle (by blocking the increase in
p21) and cell death by preventing the proteolytic activa-
tion of Bax (Figure 3 panel B).
In the parental MCF-7 cells, TNFalpha induces a dose
dependent decrease in ERalpha expression by 48 h (Fig-
ure 4 panel A). In contrast, tamoxifen induces a slight
increase in ERalpha levels in the untransfected cells. In
MCF-7CLU cells the changes in ERalpha expression are
substantially reduced but not completely abrogated (Fig-
ure 4 panel B).
In vivo, over-expression of secretory clusterin has a
dramatic effect on the growth rate of orthotopic xeno-
grafts. As shown in Figure 5 panel A, MCF-7 cells grow
slowly, even in estradiol supplemented mice. In contrast,
MCF-7CLU cells grow more rapidly, reaching an aver-
a g ev o l u m eo f8 0 0m m
3 by 10 weeks, although the
growth rate of individual tumors is quite variable.
Tamoxifen significantly decreases the volume of the
tumors derived from untransfected MCF-7 cells, but has
no statistically significant effect on the volume of MCF-
7CLU tumors (Figure 5, panel B). This is reflected in
the decrease in the proportion of replicating cells in
tumors derived from untransfected MCF-7 cells com-
pared to MCF-7CLU cells (Figure 5 panel C), and the
relative increasing rate of apoptosis in the MCF-7
tumors after treatment with tamoxifen compared to the
MCF-7CLU tumors which show a small, but significant
increase in the percentage of apoptotic cells (Figure 5
panel D). Over-expression of secretory clusterin also
increases the invasiveness of the transfected cells in
vitro (Figure 6 panel A), and a significant number of pri-
mary tumors displayed metastatic progression to the
lungs and lymph nodes in vivo (Figure 6 panel B and
Table 3).
Discussion
The data presented here demonstrate that over-expres-
sion of secretory clusterin alters the phenotypic behavior
of MCF-7 breast cancer cells. The decrease in the pro-
portion of MCF-7CLU cells undergoing apoptosis, with-
out a concomitant change in the rate of proliferation
results in a more rapid increase in cell number even in
unstressed cells. MCF-7CLU cells are also significantly
less sensitive to either the anti-estrogen, tamoxifen, or
the cytokine, TNFalpha, both of which are known to
induce apoptosis in the parental cell line. The reduced
sensitivity of the MCF-7CLU to these biological modi-
fiers is manifested by a decrease in apoptotics staining
and the abrogation of their effects on proliferation (as
measured by ApoBrdU and PI staining respectively)
compared to the untransfected parental cell. These
effects are mirrored by the abrogation of the increase in
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Page 6 of 14Figure 2 Effect of TNFalpha and tamoxifen on MCF-7 and MCF-7CLU cell adherent cell number. Panel A: MCF-7 (black bars)a n dM C F -
7CLU (grey bars) cells were plated at 20,000 cells per well and allowed to grow for the indicated times. Total adherent cell number was
determined by crystal violet staining. Panel B: MCF-7 and MCF-7CLU cells were plated at 10,000 cells per well. Two days later cells were treated
with ethanol vehicle or varying concentrations of TNFalpha (1, 5 and 10 ng/ml) for 48 h. Panel C: MCF-7 and MCF-7CLU cells were plated at
10,000 cells per well. Two days later cells were treated with ethanol vehicle or varying concentrations of tamoxifen (1, 5 and 10 micromolar) for
72 h. Data represents mean ± SEM of four values per time point. Similar results were obtained from at least three other independent
experiments. *P < 0.05.
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response to TNFalpha. There are two possible explana-
tions for these effects. First, as has been suggested from
previous studies, clusterin may bind to TNFalpha in the
medium [23,24], substantially reducing the effective con-
centration of TNFalpha. Alternatively, in MCF-7CLU
cells treated with TNFalpha or tamoxifen, the biogenesis
of the newly synthesized cl u s t e r i nm a yb em o d i f i e d ,
altering the intracellular signaling pathways responsible
for the induction of cell cycle arrest and apoptosis. Two
different mechanisms have been proposed to account
for the changes in clusterin biogenesis. It has been sug-
gested that under stress conditions the splicing of the
clusterin primary transcript is altered, producing a
mature mRNA that is translated on free ribosomes from
an alternative start site resulting in a truncated protein
that can be translocated to the nucleus [35]. Over-
expression of this clusterin isoform, which binds to
Ku70/80 has been shown to induce apoptosis in MCF-7
cells [13]. In the current studies, we have not been able
to identify the variant RNA using RT-PCR, nor have we
identified a protein of the appropriate molecular mass
(49 kDa) by Western analysis (data not shown). Our
previous studies have suggested that in MCF-7 cells
clusterin biogenesis is altered by profound changes in
the post-translational modifications that occur after
treatment with tamoxifen. These changes appear to
occur after the full length mRNA has been translated by
bound ribosomes [12]. During the process of co-transla-
tional translocation through the translocons of the
endoplasmic reticulum, nascent clusterin is normally
glycosylated by oligosaccharyltransferase a process that
is regulated in part by Ost2p (DAD-1, defender against
death-1) [36,37]. The glycoprotein is then further modi-
fied and disulfide bonded in the ER, translocated to the
Golgi, and cleaved to form the mature alpha and beta
disulfide linked chains in the trans Golgi [12]. Over-
expression of clusterin or other secretory proteins does
not appear to induce an ER-overload response [38], and
it is unlikely that the glycosylation, processing or traf-
ficking of the glycoprotein is altered as a consequence
of over-expression. In MCF-7 cells, during apoptosis
induced by TNFalpha or anti-estrogen treatment, clus-
terin expression is significantly upregulated [12]. How-
ever, Ost2p/DAD-1 is also inactivated [39,40] and the
initial glycosylation of clusterin (and other glycopro-
teins) is abrogated as the structural integrity of the oli-
gosaccharyltransferase is compromised [41]. While this
does not interfere with the translation or translocation
of the nascent protein, or its subsequent folding and dis-
ulfide bond formation, the non-glycosylated protein is
not cleaved into the mature heterodimer in the Golgi.
This induces ER overload [38] resulting in the appear-
ance of the uncleaved, disulfide-linked protein in the
nucleus of dying cells [12]. The retro-translocation of
clusterin from the endomembrane system to the cyto-
plasm has recently been confirmed [42], providing an
important missing component in the biosynthesis of the
disulfide linked nuclear isoform. These latter studies
also provide a rational explanation for the presence of
the protein in the cytoplasmic compartment where it
has been shown to influence TGFbeta-mediated signal-
ing and inhibit apoptosis through a direct interaction
with activated Bax [43].
The observation that clusterin over-expression also
stimulates invasion and metastatic progression, at least
to the lungs, suggests that the secreted glycoprotein has
additional extracellular functions. This increase in the
number of metastatic sites does not appear to correlate
simply with the increased size of the MCF-7CLU pri-
mary tumors, although we cannot definitively rule out
this possibility. In our view it is more likely that secre-
tory clusterin plays one or more distinct roles in the
metastatic spread of the cells from the primary tumor.
Table 1 Effects of TNFalpha and Tamoxifen on MCF-7 and MCF-7CLU cell cycle kinetics.
G0/G1 SG 2/M
MCF-7 MCF-7CLU MCF-7 MCF-7CLU MCF-7 MCF-7CLU
Control 61.6 ± 2.8 52.8 ± 2.5* 27 ± 2.1 35.2 ± 4.0* 12.4 ± 1.8 11.5 ± 3.8
Tamoxifen (5 micromolar) 75.2 ± 3.4 60 ± 3.0* 14.5 ± 4.0 31.7 ± 2.1* 9.5 ± 3.0 8.3 ± 1.9
TNF-alpha (5 ng/ml) 72.8 ± 1.4 56.3 ± 2.2* 15.3 ± 3.8 41.9 ± 3.4* 11.9 ± 2.0 1.6 ± 1.2*
MCF-7 and MCF-7 CLU cells were grown in culture and treated with ethanol vehicle, TNFalpha (5 ng/ml) or tamoxifen (5 micromolar) for 48 h. Cells were
harvested, ethanol fixed and stained with propidium iodide and analyzed by flow cytometry. Results are expressed as mean ± SD of three independent
replicates. (* indicates significant differences between means (MCF-7 versus MCF-7CLU), p < 0.05).
Table 2 Effects of TNFalpha and Tamoxifen on MCF-7
and MCF-7CLU DNA fragmentation.
Percentage Apoptotic Cells MCF-7 MCF-7CLU
Control 13.6 ± 1.4 7.4 ± 1.2*
Tamoxifen (5 micromolar) 22.2 ± 2.8 5.6 ± 1.4*
TNFalpha (5 ng/mL) 22.6 ± 1.8 6.4 ± 1.8*
MCF-7 and MCF-7 CLU cells were grown in culture and treated with ethanol
vehicle, TNFalpha (5 ng/ml) or tamoxifen (5 micromolar) for 48 h as described
in Materials and Methods. DNA strand breaks were labeled with Br-dUTP and
detected using a FITC-conjugated anti-BrdU antibody and analysed by flow
cytometry as described in Materials and Methods. Data are expressed as the
percentage of cells positive for DNA fragmentation. Results are expressed as
mean ± SD of three independent replicates. (* indicates significant differences
between means (MCF-7 versus MCF-7CLU), p < 0.05).
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Page 8 of 14Figure 3 Effect of TNFalpha on p21 and Bax in MCF-7 and MCF-7CLU cells. Panel A: Nuclear extracts prepared from MCF-7 and MCF-7CLU
cells treated with ethanol or 5 ng/ml TNFalpha for 48 h were separated on 10% SDS-PAGE gels and immunoblotted with mouse monoclonal
antibodies against p21. Nuclear p21 protein expression was normalized against lamin A/C and plotted relative to appropriate control. Blots are
representative of two independent experiments. Panel B: Cytosolic fractions prepared from MCF-7 and MCF-7CLU cells treated with ethanol
vehicle or 5 ng/ml TNFalpha for 48 h were separated on 12.5% SDS-PAGE gels and immunoblotted with monoclonal antibodies directed against
bax and GAPDH. Non-nuclear membrane (NNMF) fractions were separated on 12.5% SDS-PAGE gels and immunoblotted with monoclonal
antibodies directed against Bax, GAPDH and ATP synthase. Blots are representative of two independent experiments. Data are expressed as
mean ± range.
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Page 9 of 14Figure 4 Effects of TNFalpha and tamoxifen on ERalpha expression in MCF-7 and MCF-7CLU cells. Total cell lysates prepared from MCF-7
(Panel A) and MCF-7CLU (Panel B) cells treated with ethanol vehicle, TNFalpha (1, 2.5 and 5 ng/ml) or tamoxifen (1, 2.5 micromolar) in serum
free medium for 48 h were separated on 10% SDS-PAGE gels and immunoblotted with mouse monoclonal antibodies against ERalpha and
GAPDH. Individual band intensity was normalized against GAPDH and plotted relative to appropriate control. Blots are representative of three
independent experiments. Results are expressed as Mean ± SD, *, p < 0.05 (control versus treated).
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Page 10 of 14Figure 5 Response of MCF-7 and MCF-7CLU cells grown as orthotopic xenografts to tamoxifen. Panel A: Ovariectomized nude mice
supplemented with slow release estradiol pellets (1.7 mg/90 day) were inoculated with MCF-7 or MCF-7CLU cells and allowed to grow for 4-5
weeks. *P < 0.05; MCF-7 vs MCF-7CLU. (n = 10-12). Panel B: Ovariectomized nude mice supplemented with slow release estradiol pellets (1.7
mg/90 day) were inoculated with MCF-7 or MCF-7CLU cells and allowed to grow for 4-5 weeks until tumors measured 200 mm
3. Animals were
implanted with slow release placebo or tamoxifen pellets. Results are expressed as mean ± SD. *P < 0.05 (control versus treated, n = 10). Panel
C: Formalin-fixed sections from placebo or tamoxifen treated MCF-7 or MCF-7CLU tumors were labeled for cellular proliferation using PCNA.
Representative sections stained for PCNA (scale bar: 50 micrometers). Positive cells were counted as a percentage of total cells. A minimum of
500 cells from each of two sections from four mice per treatment group were evaluated. *P < 0.05 control vs treated. Panel D: Formalin-fixed
sections from placebo or tamoxifen (15 mg/60 day) treated MCF-7 or MCF-7CLU tumors, excised after 10 weeks of treatment, were TUNEL
labelled. Representative TUNEL-stained sections (scale bar: 50 micrometers). Positive cells were counted as a percentage of total cells. A
minimum of 500 cells from each of two sections from four mice per treatment group were evaluated. *P < 0.05 control vs treated.
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Page 11 of 14Hematogeneous spread of tumor cells is a complex pro-
cess that involves intravasation into the microvascula-
ture surrounding the primary tumor, survival of tumor
cells in the circulation and extravasation from the
microvasculature at the metastatic site [44,45]. For
many metastatic cells, survival is enhanced through
heterotypic cell-cell interactions, which promotes embo-
lus formation. Embolus formation also increases the
likelihood that invasive cells arrest in the microvascula-
ture at the metastatic site, and enhances the probability
that the cells will extravasate. It is likely that chronic
over-expression of clusterin in cells which survive ther-
apy results in the clustering of tumor cells, platelets and
other circulating cells to form emboli, possibly as a by-
product of the function of the glycoprotein as an extra-
cellular chaperone, as originally described by Fritz and
his colleagues who first described and named the pro-
tein [46].
While the experimental design used in this study can-
not exclude the possibility that some of the clusterin
synthesized within the endomembrane system is
Table 3 Frequency of macroscopic metastases in nude
mice after orthotopic implantation of MCF-7 or MCF-
7CLU cells in the inguinal fat pad of female NCR/nu mice.
Gross Morphology
Tumor Type Lymph Nodes Lung Liver
MCF-7 0/35 0/35 0/35
MCF-7CLU 26/35 11/35 1/35
Figure 6 Invasive and Metastatic Potential of MCF-7 and MCF-7CLU. Panel A: In vitro invasive potential was analysed using a Boyden
chamber Matrigel™ invasion assay. Cells that invaded through the 8 micron Matrigel™ membrane and attached to the bottom of the well were
fixed with 1% gluteraldehyde, stained with crystal violet, allowed to dry and counted using a light microscope. Data represent the mean ± SEM
of 3 independent experiments performed in quadruplicate for each cell line. SUM-159PT cells are shown as a positive control. *P < 0.05; MCF-7
vs MCF-7CLU and SUM-159PT. Panel B: Representative lung tissue sections from mice inoculated orthotopically with MCF-7 or MCF-7CLU were
formalin fixed, paraffin embedded, sectioned and stained with hematoxylin and eosin. Incidence of metastatic lung deposits was monitored in
animals 10 weeks after implantation. Arrow indicates MCF-7CLU metastatic foci to the lung. Lung sections from mice inoculated with the
metastatic SUM-159PT are shown as positive controls. Bar: 100 microns.
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Page 12 of 14retro-translocated to the nucleus even in the unstressed
cells over-expressing the secretory isoform, we were
unable to detect any nuclear clusterin prior to treatment
with TNFalpha or tamoxifen (Figure 1D and data not
shown). This suggests that the phenotypic changes seen
i nt h eu n s t r e s s e dM C F - 7 C L Uc e l l sa r ep r o b a b l yd u et o
the secretory glycoprotein rather than intracellular iso-
forms. However, it is likely that changes in endomem-
brane trafficking accompanying the response of the
MCF-7CLU cells to TNFalpha (in vitro) and tamoxifen
(in vivo) result in ER overload and the retrotranslocation
of a proportion of the nascent protein to the nucleus,
although we have been unable to detect the nuclear iso-
form during treatment with tamoxifen or TNFalpha or
in surviving cells using immunofluorescence. Thus, it is
not possible to fully delineate which of the observed
effects on the phenotype of the MCF-7CLU after treat-
ment are due to effects of the secretory isoform and
which are due to the cytoplasmic or nuclear isoforms.
In fact, it is probable that the phenotypic changes in the
MCF-7CLU cells, including their increased resistance to
cell death and the acquisition of the invasive phenotype
represents the combined effect of the extracellular and
intracellular isoforms. Further work will be required to
dissect these responses and refine the target for inter-
ventional therapies such as the anti-sense approaches
currently being pursued by others for the treatment of
prostate cancer.
Conclusions
These data demonstrate that secretory clusterin, which
is frequently up-regulated in breast cancers by common
therapies, including anti-est r o g e n s ,m a yp l a yas i g n i f i -
cant role in tumor growth and metastatic progression
by blocking the apoptotic signaling, leading to cell survi-
val and by increasing the ability of cells to survive dur-
ing one or more phases of the metastatic process.
Targeting the secreted form of clusterin may decrease
the rate of metastatic progression.
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